bioAffinity Showcases CyPath Lung Case Study in Diagnostics

bioAffinity Technologies, Inc. ( (BIAF) ) has provided an announcement.

bioAffinity Technologies, Inc., a biotechnology company specializing in noninvasive lung cancer diagnostics, on March 17, 2026 released a clinical case study on its CyPath® Lung test. CyPath® Lung uses flow cytometry, artificial intelligence and a fluorescent porphyrin to analyze sputum, and has shown 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in high-risk patients with nodules under 20 millimeters.

The case study describes a 71-year-old former smoker with multiple small pulmonary nodules whose negative CyPath® Lung result indicated an unlikely malignancy, allowing his pulmonologist to defer invasive bronchoscopy or biopsy in favor of surveillance. A follow-up CT scan in October 2025 showed resolution of suspicious nodules, supporting benign inflammation and illustrating how CyPath® Lung can improve diagnostic clarity, support physician decision-making, reduce patient anxiety and help avoid costly, potentially risky procedures.

By highlighting real-world use where a noninvasive test guided conservative management with favorable outcomes, the report underscores CyPath® Lung’s potential to strengthen bioAffinity Technologies’ positioning in lung cancer diagnostics. The data suggest meaningful implications for patients, clinicians and payers seeking accurate, less invasive options for managing indeterminate lung nodules in high-risk populations.

The most recent analyst rating on (BIAF) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Spark’s Take on BIAF Stock

According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.

The score is primarily held down by weak financial performance (widening losses and rising cash burn alongside 2025 revenue decline). Corporate events provide a partial offset via multiple positive clinical and operational milestones, while valuation is constrained by negative earnings and technical signals are largely unavailable.

To see Spark’s full report on BIAF stock, click here.

More about bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics for early-stage lung cancer and other lung diseases, as well as broad-spectrum cancer treatments. Its first product, CyPath® Lung, a high-sensitivity and high-specificity sputum-based test, is marketed as a Laboratory Developed Test under CLIA oversight through subsidiary Precision Pathology Laboratory Services.

The company targets high-risk patients with small, indeterminate pulmonary nodules, aiming to improve early detection and clinical decision-making while potentially lowering healthcare costs by reducing unnecessary invasive procedures and associated risks in lung cancer workups.

Average Trading Volume: 4,697,321

Technical Sentiment Signal: Hold

Current Market Cap: $8.59M

For a thorough assessment of BIAF stock, go to TipRanks’ Stock Analysis page.